SOUTH PLAINFIELD, N.J.,
July 24, 2017 /PRNewswire/
-- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the
promotion of Joseph McIntosh, M.D.
to Senior Vice President and Head of Clinical Development. Dr.
McIntosh will be responsible for all aspects of Clinical
Development across PTC's portfolio.
"Dr. McIntosh's extensive experience and clinical management
skills have been fundamental to PTC's development programs," said
Marcio Souza, Chief Operating
Officer, PTC Therapeutics, Inc. "Joe is a thoughtful leader
committed to developing treatments for patients with rare diseases
with significant unmet need. In this role, he will continue to help
guide our programs as we approach critical clinical and regulatory
milestones."
Dr. McIntosh joined PTC Therapeutics, Inc. in 2015 as Vice
President, Clinical Development where he has been the lead
clinician within the development group. Prior to joining PTC, Dr.
McIntosh was Executive Director of Clinical Development of NPS
Pharmaceuticals, responsible for managing and successfully
coordinating cross functional program teams. Prior to NPS, he
worked for Pfizer and Eisai where he assumed the role of clinical
lead and program team lead for variety of development programs.
Over the last several years, Joe has worked exclusively on rare
diseases where he has led several development programs across
hematology, hepatic and gastrointestinal therapeutic areas which
include the successful initiation and completion of multiple phase
3 programs. Dr. McIntosh holds a medical degree from University of
Witwatersrand, JHB, South
Africa.
About PTC Therapeutics
PTC is a global
biopharmaceutical company focused on the discovery, development,
and commercialization of novel medicines using our expertise in RNA
biology. PTC's internally discovered pipeline addresses multiple
therapeutic areas, including rare disorders and oncology. PTC has
discovered all of its compounds currently under development using
its proprietary technologies. Since its founding nearly 20 years
ago, PTC's mission has focused on developing treatments to
fundamentally change the lives of patients living with rare genetic
disorders. The company was founded in 1998 and its corporate
headquarters is located in South
Plainfield, New Jersey. For more information on the company,
please visit our website www.ptcbio.com.
For More Information:
Investors:
Emily
Hill
+ 1 (908) 912-9327
ehill@ptcbio.com
Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com
Forward-Looking Statements:
All statements, other than those of historical fact, contained in
this release are forward-looking statements, including statements
regarding PTC's strategy, future operations, future financial
position, future revenues or projected costs; and the objectives of
management. Other forward-looking statements may be
identified by the words "guidance", "plan," "anticipate,"
"believe," "estimate," "expect," "intend," "may," "target,"
"potential," "will," "would," "could," "should," "continue," and
similar expressions.
PTC's actual results, performance or achievements could differ
materially from those expressed or implied by forward-looking
statements it makes as a result of a variety of risks and
uncertainties, including the factors discussed in the "Risk
Factors" section of PTC's most recent Quarterly Report on Form 10-Q
as well as any updates to these risk factors filed from time to
time in PTC's other filings with the SEC. You are urged to
carefully consider all such factors.
The forward-looking statements contained herein represent PTC's
views only as of the date of this press release and PTC does not
undertake or plan to update or revise any such forward-looking
statements to reflect actual results or changes in plans,
prospects, assumptions, estimates or projections, or other
circumstances occurring after the date of this press release except
as required by law.
View original
content:http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-promotion-of-dr-joseph-mcintosh-to-senior-vice-president-and-head-of-clinical-development-300493076.html
SOURCE PTC Therapeutics, Inc.